In London and Paris, New Orleans and California, the conversations consistently returned to a central theme: in complex occlusive disease, crossing comes first.

Across conferences and industry meetings throughout Europe and the United States, Versono Medical has spent time listening to clinicians, researchers, investors and industry colleagues discuss some of the most persistent challenges in vascular intervention. Many of those conversations centred on the same reality: treatment cannot proceed if the lesion cannot be crossed.

For many patients with chronic total occlusions, particularly in challenging below-the-knee and below-the-ankle vessels, crossing the occlusion remains one of the most important barriers to treatment. For patients with chronic limb-threatening ischaemia, there is a high risk of amputation when revascularisation is not possible.

Much of Versono Medical’s engagement so far this year has been shaped by the reality of “no cross, no treatment” with the continuing development of our distinct ultrasonic platform for challenging occlusive disease.

FYA Congress, London – A three-day interactive vascular meeting on peripheral, venous and aortic treatments.F

In March, Versono Medical’s CEO Finbar Dolan presented to fellow professionals at this year’s Find Your Algorithm (FYA) Congress in London on “A New Frontier in Crossing CTO’s”, discussing our ultrasonic platform designed for challenging occlusive disease. Finbar explored a new approach aimed at widening the range of lesions that can be approached, particularly in difficult below-the-knee cases.

Chief Commercial Officer Mark Harty also attended the congress and together, they met and engaged with a number of industry experts across the event.

FYA is a crucial part of Versono Medical’s calendar as it focuses not only on the tools clinicians use, but on how they think through complex cases.

LSI USA, California – Gathering of MedTech innovators, investors and strategic partners to discuss emerging technologies and investment opportunities

Also in March, CEO Finbar Dolan, CCO Mark Harty, CTO Hugh O’ Donoghue, CFO Padraic Clarke and attended LSI USA in California. LSI brings together key personnel in healthcare to discuss emerging technologies and investment opportunities.

At the congress, Finbar presented our Prosonic system and discussed one of the main challenges in treating chronic total occlusions.

The presentation showed how the Prosonic system is designed to enable intraluminal crossing through complex occlusions, particularly in below-the-knee and below-the-ankle vessels, opening a pathway to revascularisation for patients who may otherwise have limited treatment options.

LSI also provided the opportunity to hear perspectives from across the MedTech ecosystem, from innovators and investors to commercial and clinical leaders.

EuroPCR, Paris – a four-day interventional cardiovascular meeting

May saw members of our team attend EuroPCR in Paris, France. EuroPCR continues to be one of the world’s leading meetings in interventional cardiovascular medicine and brings together cardiologists, surgeons, researchers, nurses and industry leaders for a scientific programme focused on the latest developments in the field.

CEO Finbar Dolan was joined by CTO Hugh O’ Donoghue to share an update on our FREEFLOW pivotal study. The U.S.-based, multi-centre study evaluates the Prosonic System across five clinical sites and is now nearing completion. At EuroPCR, the Versono team discussed the “no cross, no treatment” challenge in complex peripheral arterial disease and how the Prosonic System is being developed to support intraluminal crossing through complex occlusions in challenging anatomy.

Also discussed was our future first-in-human pilot study evaluating the Prosonic System in coronary anatomies, planned to begin early next year.

NCVH, New Orleans

We recently attended New Cardiovascular Horizons 2026 in New Orleans, joining clinicians and industry colleagues from across the global vascular community.

A forum for education, collaboration and the exchange of clinical experience, NCVH brings together vascular specialists, angiologists, surgeons, interventional radiologists and cardiologists to share perspectives on some of the most complex cases in vascular care at present.

This year’s programme offered an international perspective with cases and insights shared from centres including Houma, Louisiana, Beijing, Bad Krozingen and Abano Terme, giving those in attendance the opportunity to learn from different healthcare systems, approaches and experiences.

Versono Medical was represented by Finbar Dolan, Hugh O’ Donoghue, Pat Connolly, Lea Doyle and Dawn Burleson who engaged with clinicians, collaborators and industry colleagues throughout the week.

Other events attended

In addition, we also attended a number of other events so far this year including the Innovation Summit in Dublin – a three-day event exploring the needs, opportunities and challenges facing the global medical device industry. Also in April, we attended The Charing Cross Symposium (CX) in London. CX focuses on identifying evidence for optimal vascular disease management from head to toe, catering for all vascular specialists.

What We Heard Across the Year So Far

Across these meetings, several themes surfaced repeatedly in conversations with clinicians and industry colleagues.

The first is the growing complexity of peripheral arterial disease. Clinicians continue to face challenging anatomies, particularly in below-the-knee and below-the-ankle vessels, where treatment decisions can be difficult and options may be limited.

The second is the continued challenge of crossing chronic total occlusions. Across multiple discussions, the message remained consistent: before any therapy can be delivered, the lesion must first be crossed. In many cases, treatment begins or ends with the ability to cross the lesion.

There is increasing attention on below-the-knee disease and chronic limb-threatening ischemia patients, many of whom face a high risk of amputation when revascularisation is not possible. This reinforces the importance of technologies and approaches designed to support access through complex occlusions.

Another theme has been the recognition that many treatment decisions are shaped before treatment actually begins. Case selection, procedural planning, crossing strategy and confidence in available tools can all influence what is attempted and what is considered possible.

There was also a willingness, across multiple conversations, to question how much procedural uncertainty has become accepted in complex cases. Many of the discussions reflected an openness to new thinking and approaches that may help widen the range of lesions that can be approached.

We’re grateful to everyone who has shared their perspectives with us so far this year. Many of those conversations are ongoing, and we look forward to continuing them throughout the year.